References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLongitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis
Bruyère, Olivier ULg; Genant, H.; Kothari, M. et al

in Osteoarthritis and Cartilage (2007), 15(1), 98-103

Objective: To investigate, over 1-year, the relationship between X-ray and magnetic resonance imaging (MRI) findings in patients with knee osteoarthritis (OA). Methods: Sixty-two osteoarthritic patients ... [more ▼]

Objective: To investigate, over 1-year, the relationship between X-ray and magnetic resonance imaging (MRI) findings in patients with knee osteoarthritis (OA). Methods: Sixty-two osteoarthritic patients (46 women) were followed for 1 year. At baseline and after 1 year, volume and thickness of cartilage of the medial tibia, the lateral tibia and the femur were assessed by MRI. A global score from the multi-feature whole-organ MRI scoring system (WORMS) was calculated for each patient at baseline and after 1 year. This score combined individual scores for articular cartilage, osteophytes, bone marrow abnormality, subchondral cysts and bone attrition in 14 locations. It also incorporated scores for the medial and lateral menisci, anterior and posterior cruciate ligaments, medial and lateral collateral ligaments and synovial distension. Lateral and medial femorotibial joint space width (JSW) measurements, performed by digital image analysis, were assessed from fixed-flexion, postero-anterior knee radiographs. Results: One-year changes in medial femoro-tibial JSW reach 6.7 (20.5) % and changes in medial cartilage volume and thickness reach 0.4 (16.7) % and 2.1 (11.3) %, respectively. Medial femoro-tibial joint space narrowing (JSN) after 1 year, assessed by radiography, was significantly correlated with a loss of medial tibial cartilage volume (r = 0.25, P = 0.046) and medial tibial cartilage thickness (r = 0.28, P = 0.025), over the same period. We found also a significant correlation between the progression of the WORMS and radiographic medial JSN over 1 year (r = -0.35, P = 0.006). All these results remained statistically significant after adjusting for age, sex and body mass index. Conclusion: This study shows a moderate but significant association between changes in JSW and changes in cartilage volume or thickness in knee joint of osteoarthritic patients. (C) 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailInjectable bisphosphonates for the treatment of osteoporosis.
Reginster, Jean-Yves ULg; Burlet, Nansa; Close, P. et al

in Women's Health (2007), 3(6), 719-23

Bisphosphonates are the current mainstay of the management of osteoporosis worldwide. Oral daily and weekly formulations have been linked to poor adherence, yielding a decrease in antifracture efficacy ... [more ▼]

Bisphosphonates are the current mainstay of the management of osteoporosis worldwide. Oral daily and weekly formulations have been linked to poor adherence, yielding a decrease in antifracture efficacy, in real-life settings. Development of new bisphosphonates, with increased antiosteoclastic potency and affinity for bone matrix allowed intravenous administration and intervals between dosings to be higher than weekly. Ibandronate and zoledronic acid have been investigated in established osteoporosis. Quarterly injections of ibandronate (3 mg) have been shown to be at least as effective in increasing bone mineral density and reducing bone turnover markers as the oral ibandronate regimen, which has proven antifracture efficacy. A once-yearly infusion of zoledronic acid (5 mg) during a 3-year period significantly reduced the risk of vertebral, hip and other fractures. Intravenous administration of bisphosphonates can now be considered as an important component of the management of postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 24 (16 ULg)
Full Text
Peer Reviewed
See detailGlucosamine and chondroitin sulfate as therapeutic agents for knee and hip Osteoarthritis
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Drugs & Aging (2007), 24(7), 573-580

Osteoarthritis (OA), the most common form of arthritis, is a public health problem throughout the world. Several entities have been carefully investigated for the symptomatic and structural management of ... [more ▼]

Osteoarthritis (OA), the most common form of arthritis, is a public health problem throughout the world. Several entities have been carefully investigated for the symptomatic and structural management of OA. This review evaluates published studies of the effect of glucosamine salts and chondroitin sulfate preparations on the progression of knee or hip OA. Despite multiple double-blind, controlled clinical trials of the use of glucosamine and chondroitin sulfate in OA, controversy regarding the efficacy of these agents with respect to symptomatic improvement remains. Several potential confounders, including placebo response, use of prescription medicines versus over-the-counter pills or food supplements, or use of glucosamine sulfate versus glucosamine hydrochloride, may have relevance when attempting to interpret the seemingly contradictory results of different clinical trials. The National Institutes of Health-sponsored GAIT (Glucosamine/chondroitin Arthritis Intervention Trial) compared placebo, glucosamine hydrochloride, chondroitin sulfate, a combination of glucosamine and chondroitin sulfate and celecoxib in a parallel, blinded 6-month multicentre study of patients with knee OA. This trial showed that glucosamine hydrochloride and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with OA of the knee. However, exploratory analyses suggest that the combination of glucosamine hydrochloride and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain. For decades, the traditional pharmacological management of OA has been mainly symptomatic. However, in recent years, several randomised controlled studies have assessed the structure-modifying effect of glucosamine sulfate and chondroitin sulfate using plain radiography to measure joint space narrowing over years. There is some evidence to suggest a structure-modifying effect of glucosamine sulfate and chondroitin sulfate. On the basis of the results of recent randomised controlled trials and meta-analyses, we can conclude that glucosamine sulfate (but not glucosamine hydrochloride) and chondroitin sulfate have small-to-moderate symptomatic efficacy in OA, although this is still debated. With respect to the structure-modifying effect, there is compelling evidence that glucosamine sulfate and chondroitin sulfate may interfere with progression of OA. [less ▲]

Detailed reference viewed: 137 (10 ULg)
Full Text
Peer Reviewed
See detailPrevention of hip fractures in osteoporosis
Neuprez, Audrey ULg; Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg et al

in Minerva Ortopedica e Traumatologica (2007), 58(5), 423-437

Hip fracture is the major clinical consequence of osteoporosis. It is linked with decreased life expectancy and quality of life, placing an ever increasing burden on health services. Few medications have ... [more ▼]

Hip fracture is the major clinical consequence of osteoporosis. It is linked with decreased life expectancy and quality of life, placing an ever increasing burden on health services. Few medications have unequivocally demonstrated their ability to reduce hip fracture risk in osteoporotic subjects. Daily alendronate and risedronate reduce hip fracture in patients with low bone mineral density and prevalent vertebral fractures. Intravenous bisphosphonates have been developed, in response to long-term poor adherence to oral anti-osteoporotic treatments. Once-yearly zoledronic acid reduces fracture rates at the spine, non-spine and hip locations. Strontium ranelate, the first drug to uncouple bone formation from bone resorption has also demonstrated its ability to reduce hip fractures in patients above 74 years old, with prevalent low bone mineral density. Calcium and vitamin D supplementation are prerequisite for the management of elderly subjects and should always been associated to anti-resorptive or bone forming agents. Non-pharmacological management of osteoporosis is recommended cannot be considered a substitute for pharmacological treatment of osteoporosis, not even in old age. [less ▲]

Detailed reference viewed: 104 (10 ULg)
Full Text
Peer Reviewed
See detailIntraveinous paracetamol: a review of efficacy and safety in therapeutic use
Malaise, Olivier ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Future Neurology (2007), 2(6), 673-688

Paracetamol is well established as a leading nonprescription antipyretic analgesic drug and is available in oral, rectal or intravenous forms. However, except for oral paracetamol, there is a marked ... [more ▼]

Paracetamol is well established as a leading nonprescription antipyretic analgesic drug and is available in oral, rectal or intravenous forms. However, except for oral paracetamol, there is a marked discrepancy between the extent to which paracetamol is used and the available evidence for an analgesic effect in postoperative pain. This review mainly focuses on intravenous paracetamol. Its efficacy and safety are analyzed, as well as its use in therapeutics, alone or in combination. The morphine-sparing, additive and antihyperalgesia effects of intravenous paracetamol are also reviewed. The analyses are divided into several sections, comparing the efficacy of intravenous paracetamol with placebo, other forms of paracetamol or analgesic agents and analyzing its efficacy in multimodal therapy combined with NSAIDs or a morphinic agent. [less ▲]

Detailed reference viewed: 129 (7 ULg)
See detailEpidémiologie de l'environnement
Bruyère, Olivier ULg

Learning material (2007)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailStructure modification in osteoarthritis
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in European Musculoskeletal Review (2007)

For decades, the traditional pharmacological management of osteoarthritis (OA) has been mainly symptomatic, despite a lack of evidence of its influence on the duration of the disease and its progression ... [more ▼]

For decades, the traditional pharmacological management of osteoarthritis (OA) has been mainly symptomatic, despite a lack of evidence of its influence on the duration of the disease and its progression. However, in recent years several sets of guidelines, recommendations or points to consider have been issued by regulatory authorities or scientific groups regarding requirements for the registration of drugs to be used in the treatment of OA. The ideal outcomes currently include pain and function assessment for symptom-modifying drugs, and joint-space narrowing (JSN) assessed by plain radiography for structure-modifying compounds. Taking advantage of these more precise recommendations, several chemical entities have been carefully investigated for the management of OA. This article provides a summary of the available evidence demonstrating that some compounds can effectively interfere with the structural progression of the disease. Avocado/Soybean Unsaponifiables The unsaponifiable part of avocado (A) and soybean (S) oils (ASU) mixed in a ratio of 1:2 (A1:S2) has been investigated in the treatment of connective tissues, including in OA, for several years. A pilot randomised, double-blind, placebo-controlled trial with follow-up over two years failed to demonstrate a structural effect of ASU in 163 patients with painful hip OA.1 However, in a post hoc analysis a significant difference was detected in the subgroup with a baseline joint-space width (JSW) smaller than 2.45mm: joint space loss was halved in the treated group (-0.43±0.51mm) compared with the placebo group (-0.86±0.62mm; p=0.01). This finding suggests that ASU may have a structure-modifying effect in patients with severe hip OA. Chondroitine Sulphate Chondroitine sulphate (CS) is a major component of the extra-cellular matrix from many connective tissues, including – but not limited to – cartilage, bone, skin, ligaments and tendons. In the articular cartilage, the high content of CS in the aggrecan plays a major role in creating considerable osmotic swelling pressure, which expands the matrix and places the collagen network under tension. In a pilot double-blind study, JSW measurement on digitalised radiographs of the extended knees was used to compare the effects of CS 800mg/day and a placebo in patients with knee OA.2 There were 23 patients in each group. After one year, JSW was unchanged in the treated group but had decreased by 0.4mm in the placebo group (p<0.005). No significant difference was found for JSW at the narrowest site. The small number of patients for whom end-point values were available (12 in the placebo group and 14 in the CS group) limits the relevance of the results. Another study randomised a total of 120 patients with symptomatic knee OA into two groups receiving either 800mg CS or placebo per day for two periods of three months during one year.3 Radiological progression was assessed as a secondary outcome by automatic measurement of medial femoro-tibial JSW on weight-bearing X-rays of both knees. Radiological progression at month 12 showed significantly decreased JSW in the placebo group, with no change in the CS group. [less ▲]

Detailed reference viewed: 32 (5 ULg)
Full Text
Peer Reviewed
See detailCorrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
Bruyère, Olivier ULg; Cormier, C.; Fardellone, Patrice et al

in Revue du Rhumatisme (2006, December), 73

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailIncrease in femoral neck bone mineral density is associated with decrease in hip fracture incidence during treatment with strontium ranelate
Bruyère, Olivier ULg; Delmas, Pierre D; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2006, November), 54(Suppl), 586

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailEuropean postmenopausal osteoporotic women have high prevalence of vitamin D inadequacy
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Arthritis and Rheumatism (2006, November), 54(Suppl), 585

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailCommentary: osteoarthritis of the knee and glucosamine
Altman, R. D.; Abramson, S.; Bruyère, Olivier ULg et al

in Osteoarthritis and Cartilage (2006), 14(10), 963-966

Detailed reference viewed: 82 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study
Bruyère, Olivier ULg; Collette, Julien ULg; Kothari, M. et al

in Annals of the Rheumatic Diseases (2006), 65(8), 1050-1054

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes ... [more ▼]

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes with knee osteoarthritis were followed prospectively for one year. From magnetic resonance imaging ( MRI), done at baseline and after one year, the volume and thickness of cartilage of the femur, the medial tibia, and the lateral tibia were assessed. A whole organ magnetic resonance imaging score ( WORMS) of the knee was calculated for each patient at baseline and at the one year visits. This score consists in a validated, semiquantitative scoring system for whole organ assessment of the knee in osteoarthritis using MRI. Biochemical markers ( serum hyaluronic acid, osteocalcin, cartilage glycoprotein 39 ( YKL-40), cartilage oligomeric matrix protein ( COMP), and C-telopeptide of type I collagen ( CTX-I), and urine C-telopeptide of type II collagen ( CTX-II)) were measured at baseline and after three months. Results: Baseline markers were not correlated with one year changes observed in cartilage volume and thickness. However, an increase in CTX-II after three months was significantly correlated with a one year decrease in mean thickness of medial tibial and lateral tibial cartilage. Patients in the highest quartile of three month changes in CTX-II experienced a mean loss of 0.07 ( 0.08) mm of their medial thickness, compared with a mean increase of 0.05 ( 0.19) mm for patients in the lowest quartile ( p = 0.04) Multiple regression analysis showed that high baseline levels of hyaluronic acid are predictive of a worsening in WORMS ( p = 0.004). Conclusions: These results suggest that a single measurement of serum hyaluronic acid or short term changes in urine CTX-II could identify patients at greatest risk of progression of osteoarthritis. [less ▲]

Detailed reference viewed: 39 (6 ULg)
Full Text
Peer Reviewed
See detailClinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg; Giacovelli, Giampaolo et al

in Arthritis and Rheumatism (2006), 54(7), 2339-2341

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailSelf-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage
Richy, Florent; Bruyère, Olivier ULg; Maassen, P. et al

in Osteoporosis International (2006, June), 17(Suppl.2), 45-46

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailYoung postmenopausal women have high prevalence of inadequate serum vitamin D levels: results of a European study
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 56

Detailed reference viewed: 25 (3 ULg)